<?xml version="1.0" encoding="UTF-8"?>
<p>Tuberculosis (TB) is considered to be the world’s top infectious killer
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>. It is a complicated devastating disease that accounts for the death of 1.5 million individuals in 2018 as declared by WHO
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>. About 23% of the world’s population is expected to be latent TB carriers with a high risk to develop the disease
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>. The first-line drugs such as Isoniazid, Rifampicin, Ethambutol, and Streptomycin have shown significant activity against 
 <italic>Mycobacterium tuberculosis</italic> however, the emergency of drug-resistant TB (DR-TB), especially multi-drug resistant TB (MDR-TB) is still a serious trouble
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3</sup>
 </xref>. The emerged drug resistance can be considered as a global health crisis, where only one out of three accessing proper remedy among the patients falling ill in 2018
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>.
</p>
